Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 4,205 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Injectable Placebo Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss

NCT04462198
View directory record Official record
Conditions
Sensorineural Hearing Loss
Interventions
PIPE-505, Placebo
Drug
Lead sponsor
Contineum Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
8
States / cities
Torrance, California • Boca Raton, Florida • New Albany, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 17, 2026, 3:03 PM EDT
Completed Phase 3 Interventional

Botox Injection for Lower Extremity Lengthening and Deformity Correction Surgery

NCT00412035
View directory record Official record
Conditions
Unequal Length of Limbs; Congenital, Lower Extremity Deformities, Congenital
Interventions
Botulinum toxin A injection, saline injection
Drug
Lead sponsor
Shriners Hospitals for Children
Other
Eligibility
5 Years to 21 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
4
States / cities
Wilmington, Delaware • Honolulu, Hawaii • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 17, 2026, 3:03 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis

NCT01860976
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
489 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
17
States / cities
Phoenix, Arizona • Colorado Springs, Colorado • Bridgeport, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 17, 2026, 3:03 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin

NCT00099320
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
21 Years to 75 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
40
States / cities
Birmingham, Alabama • La Jolla, California • San Mateo, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 17, 2026, 3:03 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Gut Barrier and Blood Vessel Inflammation in Individuals With and Without HIV

NCT02431325
View directory record Official record
Conditions
HIV
Interventions
Teduglutide, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 17, 2026, 3:03 PM EDT
Completed Phase 2 Interventional Results available

Granulocyte-Macrophage Stimulating Factor in the Treatment of Peripheral Arterial Disease

NCT01041417
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Granulocyte-Macrophage Stimulating Factor (GM-CSF), Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 80 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 17, 2026, 3:03 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)

NCT03524118
View directory record Official record
Conditions
Respiratory Tract Infection, Respiratory Syncytial Virus
Interventions
Clesrovimab, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
2 Weeks to 8 Months
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
17
States / cities
Aurora, Colorado • Homestead, Florida • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 17, 2026, 3:03 PM EDT
Active, not recruiting Phase 4 Interventional

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

NCT04929210
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
38
States / cities
Avondale, Arizona • Chandler, Arizona • Mesa, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 3:03 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2A Study to Evaluate the Safety and Effect on Exercise Challenge Testing of MEDI-528 in Adults With Asthma

NCT00590720
View directory record Official record
Conditions
Asthma
Interventions
MEDI528 50 mg, PLACEBO
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
San Diego, California • Denver, Colorado • Waterbury, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2014 · Synced Oct 17, 2026, 3:03 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome

NCT02915159
View directory record Official record
Conditions
Sjogrens Disease
Interventions
Abatacept, Placebo
Biological · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
19
States / cities
Fullerton, California • Riverside, California • Lakewood, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 17, 2026, 3:03 PM EDT
Recruiting Phase 2 Interventional

Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV

NCT06554717
View directory record Official record
Conditions
HIV-1-infection, Frailty, Impaired Physical Function, Abdominal Obesity, Aging
Interventions
Tesamorelin, Placebo, Exercise
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 17, 2026, 3:03 PM EDT
Completed Phase 2 Interventional Results available

A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)

NCT04945460
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Sotatercept 0.3 mg/kg, Placebo, Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
Drug
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
18 Years to 85 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
56
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 46 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 17, 2026, 3:03 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia

NCT01064440
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Low Dose VM202, High Dose VM202, Placebo
Biological · Other
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
18 Years to 90 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
13
States / cities
Birmingham, Alabama • Orange, California • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 17, 2026, 3:03 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)

NCT01679990
View directory record Official record
Conditions
Intermittent Claudication, Peripheral Artery Disease
Interventions
PLX-PAD Low dose, PLX-PAD high doses, Double Placebo, high dose +Placebo
Biological
Lead sponsor
Pluristem Ltd.
Industry
Eligibility
45 Years to 85 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
15
States / cities
Birmingham, Alabama • Clearwater, Florida • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 17, 2026, 3:03 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Trial of Levator Muscle Blocks Following Posterior Colporrhaphy Surgery to Reduce Post-operative Pain.

NCT03067168
View directory record Official record
Conditions
Post Operative Pain
Interventions
Bupivacaine, normal saline 0.9%
Drug
Lead sponsor
The Christ Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
3
States / cities
Kansas City, Kansas • Cincinnati, Ohio • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 17, 2026, 3:03 PM EDT
Recruiting Phase 2 Interventional

Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic

NCT06226610
View directory record Official record
Conditions
Pruritis
Interventions
Dupilumab, Placebo
Drug · Other
Lead sponsor
Akron Children's Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 17, 2026, 3:03 PM EDT
Terminated Phase 3 Interventional Results available

A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension

NCT03323749
View directory record Official record
Conditions
Primary Mitochondrial Myopathy
Interventions
elamipretide, placebo comparator, elamipretide open label treatment
Combination Product
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
16 Years to 80 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
La Jolla, California • Palo Alto, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Oct 17, 2026, 3:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients

NCT02103426
View directory record Official record
Conditions
Dialysis, Healthy Subjects, Cytomegalovirus Infection
Interventions
ASP0113, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
4
States / cities
Los Angeles, California • Orlando, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 17, 2026, 3:03 PM EDT
Completed Phase 3 Interventional Results available

Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)

NCT01730040
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Atorvastatin, Ezetimibe, Rosuvastatin, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
56
States / cities
Mobile, Alabama • Chandler, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Oct 17, 2026, 3:03 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis

NCT03816891
View directory record Official record
Conditions
Prurigo Nodularis, Pruritis
Interventions
Vixarelimab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
40
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 17, 2026, 3:03 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia

NCT03503318
View directory record Official record
Conditions
Schizophrenia
Interventions
TV-46000, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
13 Years to 65 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
73
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 58 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 17, 2026, 3:03 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria

NCT04833855
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Tezepelumab Dose 1, Tezepelumab Dose 2, Omalizumab, Placebo
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
25
States / cities
Birmingham, Alabama • Fountain Valley, California • Laguna Niguel, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 17, 2026, 3:03 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)

NCT06181435
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
43
States / cities
Scottsdale, Arizona • Tucson, Arizona • Lomita, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 17, 2026, 3:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Study of LAD603 in Healthy Subjects

NCT06200597
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LAD603, Placebo
Drug · Other
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 17, 2026, 3:03 PM EDT